Correction to Lancet Rheumatol 2022; 4: e351–61

Han MK, Antila M, Ficker JH, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol 2022; 4: e351–61—In this Article, the D-dimer data in paragraph six of the Results should have read, “D-dimer (0·490 mg/L FEU [0·300–0·955] to 0·375 mg/L FEU [0·210–0·720] with ruxolitinib and 0·480 mg/L FEU [0·300–0·890] to 0·330 mg/L FEU [0·220–0·600] with placebo).” The D-dimer data in figure 2 and in the appendix have been corrected. These corrections have been made as of Feb 19, 2024.